These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6292738)

  • 1. A circulating inhibitor of (Na+ + K+)ATPase associated with essential hypertension.
    Hamlyn JM; Ringel R; Schaeffer J; Levinson PD; Hamilton BP; Kowarski AA; Blaustein MP
    Nature; 1982 Dec; 300(5893):650-2. PubMed ID: 6292738
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood pressure in essential hypertension correlates with the concentration of a circulating inhibitor of the sodium pump.
    Moreth K; Kuske R; Renner D; Schoner W
    Klin Wochenschr; 1986 Mar; 64(5):239-44. PubMed ID: 3009961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Various properties of the Na+, K(+)-ATPase and the Mg (2+)-ATPase in erythrocytes from normotensive and hypertensive subjects].
    Canestrari F; Galli F; Gheller G; De Crescentini S; Biagiarelli B
    Boll Soc Ital Biol Sper; 1991 Jul; 67(7):659-66. PubMed ID: 1667978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Na,K-ATPase inhibitor on pressor responsiveness in patients with benign essential hypertension.
    Yamaji I; Kikuchi K; Nishimura M; Nozawa A; Hasegawa T; Kobayakawa H; Komura H; Iimura O
    Am J Hypertens; 1990 Mar; 3(3):176-81. PubMed ID: 2157465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gossypol, ouabain and vanadate on the isolated perfused rat kidney and Na, K-ATPase.
    Pathak HK; Corder CN; Suman N
    Zhongguo Yao Li Xue Bao; 1984 Mar; 5(1):52-7. PubMed ID: 6326465
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for a circulating Na,K-pump inhibitor in essential hypertension.
    Hilton PJ
    Scand J Clin Lab Invest Suppl; 1986; 180():65-71. PubMed ID: 3012764
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na+-K+-ATPase.
    Haupert GT; Carilli CT; Cantley LC
    Am J Physiol; 1984 Dec; 247(6 Pt 2):F919-24. PubMed ID: 6095682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of a circulating inhibitor of Na+-K+-ATPase in essential hypertension.
    de Wardener HE; MacGregor GA
    Am J Nephrol; 1983; 3(2-3):88-91. PubMed ID: 6307047
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of vanadate on ouabain binding and inhibition of (Na+ + K+)-ATPase.
    Myers TD; Boerth RC; Post RL
    Biochim Biophys Acta; 1979 Nov; 558(1):99-107. PubMed ID: 227460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition by vanadium of sodium and potassium dependent adenosinetriphosphatase derived from animal and human tissues.
    Nechay BR; Saunders JP
    J Environ Pathol Toxicol; 1978; 2(2):247-62. PubMed ID: 216760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predominance of high molecular weight plasma Na(+)-K(+)-ATPase inhibitor in essential hypertension.
    Gonick HC; Weiler EW; Khalil-Manesh F; Weber MA
    Am J Hypertens; 1993 Aug; 6(8):680-7. PubMed ID: 8217031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Na+-K+-ATPase inhibitors and renin release: relationship to calcium.
    Cruz-Soto M; Benabe JE; López-Novoa JM; Martínez-Maldonado M
    Am J Physiol; 1984 Oct; 247(4 Pt 2):F650-5. PubMed ID: 6093556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Affinity chromatographic study of the changes in the endogenous Na+-K+-ATPase inhibitor during sodium loading in man].
    Cloix JF; Henning G; Crabos M; Delva P; Meyer P
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1251-5. PubMed ID: 6098236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ouabain-like and non-ouabain-like factors in plasma of patients with essential hypertension.
    Masugi F; Ogihara T; Hasegawa T; Kumahara Y
    Clin Exp Hypertens A; 1987; 9(7):1233-42. PubMed ID: 3040306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Na-K-adenosine triphosphatase and cation content in the erythrocyte in essential hypertension.
    Rahman M; Koh H; Primera MI; Del Greco F; Quintanilla AP
    J Lab Clin Med; 1986 Apr; 107(4):337-41. PubMed ID: 3007645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raised concentration of a circulating Na+-K+-ATPase inhibitor in essential hypertension.
    de Wardener HE; Fenton S; Alaghband-Zadeh J; MacGregor GA
    Contrib Nephrol; 1982; 30():185-91. PubMed ID: 6288322
    [No Abstract]   [Full Text] [Related]  

  • 17. The relation of the natriuretic hormone to essential hypertension.
    de Wardener HE; MacGregor GA
    Postgrad Med J; 1983; 59 Suppl 2():74-7. PubMed ID: 6310538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification of a Na+/K+ ATPase inhibitor from borderline hypertensives' plasma.
    Boschi S; Borghi C; Munarini A; Costa FV; Lu ZR; deVries D; Ambrosioni E
    Biochem Biophys Res Commun; 1990 Jun; 169(2):360-8. PubMed ID: 2162662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in plasma ouabainlike inhibitor of Na+, K+-ATPase with high sodium intake in patients with essential hypertension.
    Hasegawa T; Masugi F; Ogihara T; Kumahara Y
    J Clin Hypertens; 1987 Dec; 3(4):419-29. PubMed ID: 2839625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Circulating inhibitor of the Na+-K+ pump in essential hypertension. Physiological and pharmacological variations].
    Pernollet MG; de Thé H; Delva P; Wauquier I; Devynck MA; Baudouin-Legros M; Deray G; Rosenfeld J; Meyer P
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1283-7. PubMed ID: 6098238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.